Codex

MET trades near this level because the market is giving credit for durable capital return and strong cash generation, but discounting earnings volatility from claims experience, investment/derivative noise, and pension-risk-transfer mix. The single rerating metric is adjusted ROE trajectory versus management's 15%-17% objective; the current proxy is around 11.9%.

The stock is back above the 50-day average but still below the 200-day average, consistent with a stabilization phase rather than full rerating.

Revenue and Earnings Power

EPS execution improved in 2H-2025 after a weak middle stretch, but full-year net income still declined versus 2024 despite higher revenue.

Cash Generation and Capital Allocation

Capital return is not cosmetic: shares outstanding fell by about 27% since 2020, which supports per-share value even when accounting earnings are volatile.

Balance Sheet Stress and Flexibility

Debt is manageable versus cash, but the sharp post-2021 equity compression pushed leverage ratios materially higher, making quarterly reserve and investment outcomes more consequential for valuation.

Insurance-Specific Drivers from Warren

Group Benefits, RIS, and Asia are the core earnings pillars; Corporate & Other remains the volatility sink, so mix quality matters as much as aggregate growth.

Peer Positioning and Critical Rerating Chart

The numbers confirm MET has strong cash conversion and meaningful per-share compounding from buybacks. They contradict a simple value-only case because profitability and leverage quality still look cyclical versus the ROE target framework. Next quarter, the key watch is whether ROE and earnings quality improve together without sacrificing capital return or liquidity discipline.